Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of GLPG1972 Formulations
NCT03143725Phase 1Completed
- Sponsor
- Galapagos NV
- Start
- Apr 2017
- Primary completion
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of GLPG1972 in osteoarthritis (OA) (4 arms), sponsored by Galapagos NV. Primary endpoints: Maximum Observed Plasma Concentration at 48 hours, Plasma Concentration at 24 Hours and 2 more. Started Apr 2017; status: completed.
02
Drugs
GLPG1972
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT03143725.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03143725.